NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	<ol> <li>This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.</li> </ol>
P	2. This application does not contain, as a separate part of the disclosure on paper copy, a *Sequence Listing* as required by 37 C.F.R. 1.821(c).
4	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not edimply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	<ol> <li>The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).</li> </ol>
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Αģ	plicant Must Provide:
Ø	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
Ø	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE





### RAW SEQUENCE LISTING PATENT APPLICATION US/09/027,777B

DATE: 06/07/1999 TIME: 12:17:23

INPUT SET: S32130.raw

This Raw Listing contains the General Information Section and up to the first 5 pages.

1		SEQUENCE LISTING	
2 3	(1) Gen	eral Information:	P==
4	(I) Gen	neral Information: ENTERE	
5 6 7 8	(i)	APPLICANT: IMMER, Hansueli FORSSMANN, Wolf-Georg ADERMANN, Knut KLESSEN, Christian	
10	(ii)	TITLE OF INVENTION: PROCESS AND INTERMEDIATE PRODUCTS FOR	
11	PREPARIN	G CARDIODILATIN FRAGMENTS AND HIGHLY PURIFIED CARDIODILATIN	
· 12	FRAGMENT	'S	
13			
14	(iii)	NUMBER OF SEQUENCES: 11	
15 16	/ 1 22 \	CORRESPONDENCE ADDRESS:	
17	(14)	(A) ADDRESSEE: Nikaido, Marmelstein, Murray & Oram	
18		(B) STREET: 655 Fifteenth Street, N.W., Suite 330	
19		(C) CITY: Washington	
20		(D) STATE: D.C.	
21		(E) COUNTRY: USA	
22		(F) ZIP: 20005-4810	
23		TANKS TO BE TO THE TOTAL	
24	(♥)	COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk	
25 26		(B) COMPUTER: IBM PC compatible	
27		(C) OPERATING SYSTEM: PC-DOS/MS-DOS	
28		(D) SOFTWARE: PatentIn Release #1.0, Version #1.30	
29			
30	(vi)	CURRENT APPLICATION DATA:	
31		(A) APPLICATION NUMBER: US 09/027,777	
32		(B) FILING DATE: 23-FEB-1998	
33		(C) CLASSIFICATION:	
34		DDIOD ADDITION DAMA.	
35 36	(711)	PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: DE 44 20 381.0	
36 37		(B) FILING DATE: 02-JUN-1994	
38		(b) IIIIno ball. VI von 1991	
39	(vii)	PRIOR APPLICATION DATA:	
40	, ,	(A) APPLICATION NUMBER: DE 195 13 784.1	
41		(B) FILING DATE: 10-APR-1995	
42			
43	(viii)	ATTORNEY/AGENT INFORMATION:	
44		(A) NAME: Kitts, Monica C.	
45		(B) REGISTRATION NUMBER: 36,105	
46		(C) REFERENCE/DOCKET NUMBER: P1614-8019	

### RAW SEQUENCE LISTING PATENT APPLICATION US/09/027,777B

DATE: 06/07/1999 TIME: 12:17:24

47			
48		(ix) TELECOMMUNICATION INFORMATION:	
49		(A) TELEPHONE: (202) 638-5000	
50		(B) TELEFAX: (202) 368-4810	
51		(-,,	
52			
53	(2)	) INFORMATION FOR SEQ ID NO:1:	
54			
55		(i) SEQUENCE CHARACTERISTICS:	
56		(A) LENGTH: 17 amino acids	
		, , ,	
57		(B) TYPE: amino acid	
58		(C) STRANDEDNESS:	
59		(D) TOPOLOGY: linear	
60			
61		(ii) MOLECULE TYPE: peptide	
		(II) MODECODE IIFE: Pepcide	
62			
63			
64			
65			
66		(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:	
		(XI) DECOUNCE PEDCEILIION. DEC 15 NO.11.	
67			
68		Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln S	
69		1 5 10	15
70			
71		Cys	
72		<i>5,5</i>	
73			
74	(2)	) INFORMATION FOR SEQ ID NO:2:	
75		·	
76		(i) SEQUENCE CHARACTERISTICS:	
77		(A) LENGTH: 15 amino acids	
78		·	
		(B) TYPE: amino acid	
79		(C) STRANDEDNESS:	
80		(D) TOPOLOGY: linear	
81		•	
82		(ii) MOLECULE TYPE: peptide	
83		(22) 1.0220022 11121 2020110	•
84		•	
85			
86			
87		(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:	
88		()	
		Tou how his tou tou Mbm his Dwo hwa Com Lou hwa h	ra for for
89		Leu Arg Ala Leu Leu Thr Ala Pro Arg Ser Leu Arg A	_
90		1 5 10	15
91			
92	(2)	) INFORMATION FOR SEQ ID NO:3:	
93	` - /	,	
94		(i) SEQUENCE CHARACTERISTICS:	
95		(A) LENGTH: 5 amino acids	
96		(B) TYPE: amino acid	
97		(C) STRANDEDNESS:	
98		(D) TOPOLOGY: linear	
99		(2) 10102001, 1211001	
77			

# RAW SEQUENCE LISTING PATENT APPLICATION US/09/027,777B

DATE: 06/07/1999 TIME: 12:17:24

		INPU1 SE1: 332130.70
100	(ii)	MOLECULE TYPE: peptide
101		
102		
103		
104		
105	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:3:
106		
107	Asn	Ser Phe Arg Tyr
108	1	5
109		
110	(2) INFO	RMATION FOR SEQ ID NO:4:
111	` ,	·
112	(i)	SEQUENCE CHARACTERISTICS:
113	, ,	(A) LENGTH: 37 amino acids
114		(B) TYPE: amino acid
115		(C) STRANDEDNESS:
116		(D) TOPOLOGY: linear
117		
118	(ii)	MOLECULE TYPE: peptide
119	<b>\</b> /	The state of the s
120		
121	(ix)	FEATURE:
122	(,	(A) NAME/KEY: Peptide
123		(B) LOCATION: 115
124		(D) OTHER INFORMATION: /note= "Xaa chain is an amino acid
125	chain of	0 - 15 amino acids."
126	••••	
127	(ix)	FEATURE:
128	(211)	(A) NAME/KEY: Peptide
129		(B) LOCATION: 3337
130		(D) OTHER INFORMATION: /note= "Xaa chain is an amino acid
131	chain of	0 - 5 amino acids."
132	ondin or	V 3 dillario doctori
133	(ix)	FEATURE:
134	(211)	(A) NAME/KEY: Cross-links
135		(B) LOCATION: 1632
136		(2) 200112011 201102
137		
138	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:4:
139	(/	
140	Xaa	Xaa
141	1	5 10 15
142	-	
143	Phe	Gly Gly Arg Met Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys
144	1110	20 25 30
145		20 25
146	Yaa	Xaa Xaa Xaa Xaa
147	Add	35
148		
140	(2) TNEO	RMATION FOR SEQ ID NO:5:
150	(2) INFO	WMNITON TOX DEG ID NO.3.
	/ 1 1	SPOURNCE CHADACTEDISTICS.
151 152	(T)	SEQUENCE CHARACTERISTICS:
152	•	(A) LENGTH: 32 amino acids

#### RAW SEQUENCE LISTING PATENT APPLICATION US/09/027,777B

DATE: 06/07/1999 TIME: 12:17:24

	INPUT SET: S32130.raw
153	(B) TYPE: amino acid
154	(C) STRANDEDNESS:
155	(D) TOPOLOGY: linear
156	(2) 10102011 111041
	(ii) MOLEGULE MUDE, pontido
157	(ii) MOLECULE TYPE: peptide
158	
159	
160	(ix) FEATURE:
161	(A) NAME/KEY: Cross-links
162	(B) LOCATION: 1127
163	
164	
165	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
166	· · · -
167	Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met
168	1 5 10 15
169	2 20 20
170	Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
171	20 25 30
	20 23 30
172	
173	AND THE PROPERTY OF THE TRACE
174	(2) INFORMATION FOR SEQ ID NO:6:
175	
176	(i) SEQUENCE CHARACTERISTICS:
177	(A) LENGTH: 14 amino acids
178	(B) TYPE: amino acid
179	(C) STRANDEDNESS:
180	(D) TOPOLOGY: linear
181	
182	(ii) MOLECULE TYPE: peptide
183	
184	
185	(ix) FEATURE:
186	(A) NAME/KEY: Modified-site
187	(B) LOCATION: 1
188	(D) OTHER INFORMATION: /product= "Modified by a Boc protecting
189	group and a tBu protecting group"
190	aroah and a coa brocecorna aroah
	(iv) PRAMIDE.
191	(ix) FEATURE:
192	(A) NAME/KEY: Modified-site
193	(B) LOCATION: 4
194	(D) OTHER INFORMATION: /note= "Modified by a tBu protecting
195	group and a Pbf protecting group"
196	
197	(ix) FEATURE:
198	(A) NAME/KEY: Modified-site
199	(B) LOCATION: 7
200	(D) OTHER INFORMATION: /note= "Modified by a Pbf protecting
201	group"
202	
203	(ix) FEATURE:
204	(A) NAME/KEY: Modified-site
205	(B) LOCATION: 8
	/2/ 200111111111111111111111111111111111

# RAW SEQUENCE LISTING PATENT APPLICATION US/09/027,777B

DATE: 06/07/1999 TIME: 12:17:25

	AND THE THEORY AND THE THE THEORY AND THE THEORY AND THE THEORY AND THE THEORY AND THE THE THE THEORY AND THE THEORY AND THE
206	(D) OTHER INFORMATION: /note= "Modified by a Pbf protecting
207	group"
208	
209	(ix) FEATURE:
210	(A) NAME/KEY: Modified-site
211	(B) LOCATION: 9
212	(D) OTHER INFORMATION: /note= "Modified by a tBu protecting
213	group"
214	
215	(ix) FEATURE:
216	(A) NAME/KEY: Modified-site
217	(B) LOCATION: 10
	(D) OTHER INFORMATION: /note= "Modified by a tBu protecting
218	, ,
219	group"
220	
221	(ix) FEATURE:
222	(A) NAME/KEY: Modified-site
223	(B) LOCATION: 11
224	(D) OTHER INFORMATION: /note= "Modified by a Acm protecting
225	group"
226	
227	
228	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
229	
230	Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly
231	1 5 10
	1 5
232	
233	(2) INFORMATION FOR SEQ ID NO:7:
234	
235	(i) SEQUENCE CHARACTERISTICS:
236	(A) LENGTH: 12 amino acids
237	(B) TYPE: amino acid
238	· ·
	(C) STRANDEDNESS:
239	(D) TOPOLOGY: linear
240	
241	(ii) MOLECULE TYPE: peptide
242	
243	
244	(ix) FEATURE:
245	(A) NAME/KEY: Modified-site
246	(B) LOCATION: 1
247	(D) OTHER INFORMATION: /product= "Modified by a Fmoc
248	protecting group and a Pbf protecting group"
249	
250	(ix) FEATURE:
250	(A) NAME/KEY: Modified-site
	·
252	(B) LOCATION: 3
253	(D) OTHER INFORMATION: /product= "Modified by a OtBu
254	protecting group"
255	
256	(ix) FEATURE:
257	(A) NAME/KEY: Modified-site
258	(B) LOCATION: 4



DATE: 06/07/1999 TIME: 12:17:25

INPUT SET: S32130.raw

Line

Error

Original Text